Evidence map›Paper›PMID 28615205›Full record

ArticleJournal of virology2017

Intrasubtype B HIV-1 Superinfection Correlates with Delayed Neutralizing Antibody Response.

Gabriel A Wagner, Elise Landais, Gemma Caballero, Pham Phung, Sergei L Kosakovsky Pond, Pascal Poignard, Douglas D Richman, Susan J Little, Davey M Smith

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Gabriel A WagnerDepartment of Medicine, University of California San Diego, La Jolla, California, USA gawagner@ucsd.edu.
Elise LandaisThe International AIDS Vaccine Initiative, Neutralizing Antibody Center, La Jolla, California, USA.
Gemma CaballeroVeterans Affairs San Diego Healthcare System, San Diego, California, USA.
Pham PhungMonogram Biosciences, Inc., South San Francisco, California, USA.
Sergei L Kosakovsky PondDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Pascal PoignardThe International AIDS Vaccine Initiative, Neutralizing Antibody Center, La Jolla, California, USA.
Douglas D RichmanDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Susan J LittleDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Davey M SmithDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
University of California, San Diego · USVA San Diego Healthcare System · USInternational AIDS Vaccine Initiative · US

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Sara Gianella Weibel · 1994 to 2026
$78.4M
Primary Infection Resource Consortium (PIRC)R24AI106039 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITTLE, SUSAN JANET · 2013 to 2021
$23.1M
UC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4M
Viral correlates of neutralizing antibody responseU19AI090970 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI POIGNARD, PASCAL · 2010 to 2014
$9.3M
Efficacy of ART to Interrupt HIV Transmission NetworksR01MH100974 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITTLE, SUSAN JANET · 2014 to 2018
$3.2M
Biomathematical analysis of viral dynamics/evolutionR01AI047745 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RICHMAN, DOUGLAS D · 2001 to 2011
$3.2M
HyPhy: Molecular Evolutionary AnalysesR01GM093939 · NIGMS · TEMPLE UNIV OF THE COMMONWEALTH · PI MUSE, SPENCER V., POND, SERGEI L KOSAKOVSKY · 2010 to 2018
$2.5M
Mentoring Translational Research in HIVK24AI100665 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SMITH, DAVID MITCHELL · 2012 to 2021
$1.5M
HIV-1 Dual Infection and Neurocognitive Impairment.K23MH105231 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WAGNER, GABRIEL ARTURO · 2016 to 2019
$813k
Biomathematical Analysis of Viral Dynamics and EvolutionR56AI047745 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI POND, SERGEI L KOSAKOVSKY · 2012 to 2012
$365k
BIOMATHEMATICAL ANALYSIS OF VIRAL DYNAMICS AND EVOLUTIONR21AI047745 · NIAID · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI RICHMAN, DOUGLAS D · 2000 to 2000
$308k
NCATS NIH HHS KL2 TR001444NIAID NIH HHS K24 AI100665NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI047745NIAID NIH HHS R21 AI047745NIAID NIH HHS R24 AI106039NIAID NIH HHS R56 AI047745NIAID NIH HHS U19 AI090970NIGMS NIH HHS R01 GM093939NIMH NIH HHS K23 MH105231NIMH NIH HHS R01 MH100974
6 · The paper itself

Abstract

Understanding whether the neutralizing antibody (NAb) response impacts HIV-1 superinfection and how superinfection subsequently modulates the NAb response can help clarify correlates of protection from HIV exposures and better delineate pathways of NAb development. We examined associations between the development of NAb and the occurrence of superinfection in a well-characterized, antiretroviral therapy (ART)-naive, primary infection cohort of men who have sex with men. Deep sequencing was applied to blood plasma samples from the cohort to detect cases of superinfection. We compared the NAb activity against autologous and heterologous viruses between 10 participants with intrasubtype B superinfection and 19 monoinfected controls, matched to duration of infection and risk behavior. Three to 6 months after primary infection, individuals who would later become superinfected had significantly weaker NAb activity against tier 1 subtype B viruses (

Indexed as

AdultAntibodies, NeutralizingCaliforniaCase-Control StudiesHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHumansImmunoglobulin GMaleNeutralization TestsSuperinfectionYoung AdultAntibodies, NeutralizingHIV AntibodiesHIV Envelope Protein gp120Immunoglobulin Gdeep sequencingHIV dual infectionHIV superinfectionneutralizing antibodiesneutralizing antibodyvaccine

Identifiers

PMID28615205
PMCPMC5553187
OpenAlexW2743162601

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.